Halo-Bio RNAi Therapeutics, Inc. is an early stage company utilizing the patented 'Multivalent RNAi Platform' to develop multi-gene targeting products for the treatment of disease. Founded in 2008, the company operates in the Biotechnology, Health and Wellness, Pharmaceutical, Logistics, and Delivery industries. Currently, there is no publicly available information about the company's headquarters or its last investment and the corresponding investors. The innovative approach taken by Halo-Bio RNAi Therapeutics, Inc. in utilizing RNAi for multi-gene targeting products provides a unique and potentially groundbreaking solution for the treatment of various diseases. As of now, the company's future potential and growth trajectory are dependent on its ability to secure investments and bring its products to market.
There is no investment information
No recent news or press coverage available for Halo-Bio RNAi Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
